XML 88 R74.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Collaboration and Licensing Agreements - Additional Information (Detail) - USD ($) $ in Thousands |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
May 17, 2018 | Apr. 30, 2022 | Oct. 31, 2020 | May 31, 2018 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Net proceeds from sales of common stock under open market sales agreement |  |  |  |  |  | $ 1,117 |
Revenue from contract with customer |  |  |  |  | $ 7,137 | 20,968 | $ 41,867
License and milestone fees [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Revenue from contract with customer |  |  |  |  |  | 910 | 15,000
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Percentage of net profit sharing |  |  | 60.00% |  |  |  |
Number of days to terminate agreement |  |  |  |  | 60 days |  |
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Percentage of net profit sharing |  |  |  | 50.00% |  |  |
License Agreement with Maruishi Pharmaceutical Co. Ltd [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Earned milestone payment |  |  |  |  |  | 1,449 |
CSL Vifor Maximum [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Potential sales-based milestone payments |  |  | $ 240,000 |  |  |  |
Affiliated Entity | CSL Vifor | License and milestone fees [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Revenue from contract with customer |  |  |  |  |  |  | $ 15,000
Affiliated Entity | CSL Vifor | Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Percentage of net profit sharing |  |  | 40.00% |  |  |  |
Affiliated Entity | Vifor Fresenius Medical Care Renal Pharma Ltd | Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Number of days to terminate agreement | 60 days |  |  |  |  |  |
Termination notice effective period | 12 months |  |  |  |  |  |
Affiliated Entity | Vifor Fresenius Medical Care Renal Pharma Ltd | Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] | License and milestone fees [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Revenue from contract with customer |  | $ 15,000 |  |  |  |  |
Affiliated Entity | Vifor Fresenius Medical Care Renal Pharma Ltd | Maximum [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Potential milestone payments | $ 440,000 |  |  |  |  |  |
Affiliated Entity | Maruishi Pharmaceutical Co., Ltd. [Member] | License Agreement with Maruishi Pharmaceutical Co. Ltd [Member] | License and milestone fees [Member] |  |  |  |  |  |  |
Collaboration and Licensing Agreements: |  |  |  |  |  |  |
Revenue from contract with customer |  |  |  |  |  | $ 1,449 |

X
- Definition Termination notice effective period. + References No definition available. + Details
Name: | cara_AgreementTerminationNoticeEffectivePeriod
Namespace Prefix: | cara_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of milestone payment receivable under the collaboration and license agreement. + References No definition available. + Details
Name: | cara_CollaborationAndLicensingAgreementMilestonePaymentReceivable
Namespace Prefix: | cara_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of days to terminate agreement upon material breach. + References No definition available. + Details
Name: | cara_NumberOfDaysToTerminateAgreementUponMaterialBreach
Namespace Prefix: | cara_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of net profits sharing. + References No definition available. + Details
Name: | cara_PercentageOfNetProfitsSharing
Namespace Prefix: | cara_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of potential milestone payment of common stock investment. + References No definition available. + Details
Name: | cara_PotentialMilestonePayment
Namespace Prefix: | cara_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of potential payment upon achievement of certain sales-based milestones. + References No definition available. + Details
Name: | cara_PotentialSalesMilestonePayment
Namespace Prefix: | cara_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=cara_LicenseAndMilestoneFeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cara_ViforFreseniusMedicalCareRenalPharmaLtdAgreementNo1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cara_ViforFreseniusMedicalCareRenalPharmaLtdAgreementNo2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cara_LicenseAgreementWithMaruishiPharmaceuticalCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=cara_CslViforMaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cara_CslViforMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cara_ViforFreseniusMedicalCareRenalPharmaLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cara_MaruishiPharmaceuticalCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |